在儿科炎症性肠病中对抗TNF治疗的精确剂量
Abigail Samuels1, Kaitlin G Whaley2,3, Phillip Minar4,5
1Department of Medicine, University of Cincinnati College of Medicine, 3333 Burnet Avenue, Cincinnati, OH, 5229, USA.
积极的治疗药物监测 (TDM) 和遗传洞察力改善了儿童炎症性肠病 (IBD) 的抗TNF生物有效性. 个性化剂量策略可以提高IBD儿童的缓解率和治疗持续时间.
科学领域:
- 儿科胃肠病学 儿科胃肠病学
- 临床药理学 临床药理学
- 免疫学 免疫学 免疫学
背景情况:
- 抗瘤缩因子 (TNF) 生物制剂对于治疗儿科炎性肠病 (IBD) 至关重要.
- 优化抗TNF治疗需要了解药物暴露,患者遗传学和免疫反应.
- 个性化医疗方法对于儿童有效的IBD治疗日益重要.
研究的目的:
- 审查反TNF治疗药物监测 (TDM) 的最新进展.
- 探索药物遗传学在儿童IBD个性化药物选择中的作用.
- 突出优化IBD儿童抗TNF治疗的策略.
主要方法:
- 对小儿IBD患者实践研究和临床试验的综述.
- 对遗传多态度 (例如,HLA-DQA1*05) 和自身药物抗体发展的数据的分析.
- 调查潜在的炎症特征和生物标志物,用于伴随性诊断.
主要成果:
- 积极的TDM针对更高的抗TNF度 (>5μg/mL) 提高了儿科IBD的缓解率和生物耐久性.
- 在IBD患者中,HLA-DQA1*05多态和自身药物抗体之间存在关联,目前正在对临床影响进行调查.
- 潜在的炎症生物标志物正在被确定为抗TNF疗法的伴侣诊断.
结论:
- 在儿科IBD中有效管理抗TNF治疗需要精确的剂量策略.
- 常规的TDM和积极的药学动力学评估对于优化抗TNF治疗结果至关重要.
- 个性化药物选择,根据TDM和药物遗传学,有望改善儿童IBD的护理.
更多相关视频
09:04DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
Published on: February 27, 2014
16:07Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method
Published on: September 16, 2017
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Drugs for Treatment of Ulcerative Colitis in IBD
